v3.26.1
Equity-Accounted Investees and Joint Business - Consolidated Statements of Profit and Loss (Details) - EUR (€)
€ in Millions
12 Months Ended
Dec. 31, 2024
Dec. 31, 2025
Shanghai RAAS Blood Products Co., Ltd.    
Equity-Accounted Investees and Joint Business    
Percentage of interest in SRAAS remaining   6.58%
Unrealized Gain (Loss) € 68  
Shanghai RAAS Blood Products Co., Ltd.    
Equity-Accounted Investees and Joint Business    
Percentage of interest in SRAAS remaining 6.58%  
Selling price € 1,608  
Fair value of SRAAS 6,58% 434  
Minus: book value of the Non-current asset held for sale and transaction costs (1,124)  
Minus: book value of the Investment accounted for using the equity method as the date of loss of the significant influence (368)  
Minus: increase of the minority interest of GDS (508)  
Other contractual obligations (10)  
Result before the reclassification of translation differences 32  
Accumulated translation differences in equity 2  
Transaction result: profit 34  
Taxes on profits in China and Spain (35)  
Result net of taxes € (1)